FDA Approves Polivy for Relapsed, Refractory Diffuse Large B-Cell Lymphoma
June 10th 2019Polatuzumab vedotin-piiq (Polivy) is a first-of-its-kind anti-CD76b antibody-drug conjugate used in combination with bendamustine plus rituximab (Rituxan) for previously-treated diffuse large B-cell lymphoma.
Read More